Obesity treatment remains one of the most significant challenges in drug development due to high variability in patient response. Despite pharmacologic advancements, one-third of patients fail to respond to obesity drugs, leading to costly and inefficient clinical trials, high dropout rates, and regulatory uncertainty.
